Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on June 19, 2019. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Capital Market under the trading symbol CAPR.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a compliance notification rather than financial performance data.
Material Changes
The material change reported is the restoration of compliance with Nasdaq Listing Rule 5550(a)(2). The company received notification from the Nasdaq Listings Qualification Department that it has regained compliance with the $1.00 minimum bid price requirement for its common stock.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks and contingencies. The document is a factual notification of the resolution of a prior listing deficiency.
Investor Verification Checklist
- Verify the current trading price of CAPR to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the company's continued compliance with other Nasdaq listing requirements beyond the minimum bid price.
- Review prior 8-K filings to understand the duration and nature of the previous non-compliance period.